You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
振東製藥(300158.SZ):龍創基藥業在研項目陰道用乳桿菌二聯活菌膠囊達到主要研究終點
格隆匯 07-30 19:47

格隆匯7月30日丨振東製藥(300158.SZ)公佈,公司參股的廣東龍創基藥業有限公司(簡稱“龍創基藥業”)在研項目“陰道用乳桿菌二聯活菌膠囊”的Ⅲ期臨牀試驗達到主要研究終點。本品為複方製劑,主要成分為格氏乳桿菌和鼠李糖乳桿菌活菌,用於由菌羣紊亂而引起的細菌性陰道病的治療。

目前細菌性陰道病(Bacterial vaginosis,BV)的常規療法多采用甲硝唑、替硝唑、克林黴素等抗生素治療。長期使用抗生素容易產生耐藥性,無法有效針對性恢復陰道微生態,公司在一項Ⅱa期的臨牀研究中表明甲硝唑的臨牀治癒率大約為40%至45%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account